Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$47.64 USD
-3.10 (-6.11%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $47.69 +0.05 (0.10%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Crinetics Pharmaceuticals, Inc. [CRNX]
Reports for Purchase
Showing records 1 - 20 ( 88 total )
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways From Our Call With Crinetics Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Initial Data From Atumelnant Phase 2 Study Suggests Another Winner for Crinetics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Paltusotine NDA Submission On Track, Eyes On Phase 2 Results Of Atumelnant at ENDO
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Long Overlooked, Graves? Disease Goes In Vogue With New Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Paltusotine Sets the New Standard in Acromegaly; We Raise Our Price Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Paltusotine Aces PATHFNDR-2 and Clears the Path to Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
With Positive Carcinoid Syndrome Data Confirmed, Paltusotine Looks to Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Eyes on PATHFNDR-2 Readout This Month; Raise Price Target to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Setting Expectations For PATHFNDR-2; A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Paltusotine Comes Up Aces Again; Price Target Up to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CRNX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tens Across the Board for Paltusotine in PATHFNDR-1; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Enthusiasm For Paltusotine is Clear With Readout on Deck; Adjusting PT to $33 With Setback for CHI Program; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from our Conversation with Crinetics Pharmaceuticals and ENDO 2023; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Previewing PATHFNDR Readouts For Paltusotine; A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D